Anti-hCD19-βGal
InvivoGen Kontakt z doradcąBispecific antibody against human CD19 and β-Gal; Negative control
Anti-hCD19-βGal is a bispecific antibody that binds to two sites: hCD19 expressed on the surface of B cells, and E. coli β-galactosidase (β-Gal). It is used as a negative control for Anti-hCD19-CD3 bispecific antibody that, alike Blinatumomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [1,2].
References:
- Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
- Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7.
